Drug Database
Back to search

United States· US:0832-0816_373dd14d-05b2-4408-e063-6394a90abf95

Deflazacort

A deflazacort product containing deflazacort, registered in United States by Upsher-Smith Laboratories, LLC. The same ATC class is registered in 8 of our 19 countries.

ATC H02AB13US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedDeflazacortATCH02AB13REGISTER NO.US:0832-0816_373dd14d…PACKS LISTED2CHECKEDJuly 5, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about deflazacortAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Deflazacort is registered in 8 of 19 countries.

Countries holding a registration under ATC H02AB13 (deflazacort), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose
Search deflazacort products by name

Deflazacort · ATC H02AB13

8 / 19 countries

  • Denmark
  • Finlandprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deflazacort costs, country by country.

Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Deflazacort · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • ES Spain$0.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
DEFLAZACORT
Manufacturer
Upsher-Smith Laboratories, LLC
Country
United States (US)
ATC code
H02AB13
ATC class
Deflazacort
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 5, 2026

Packs & prices · 2

  • ndc11
    0832081630
    1 BOTTLE in 1 CARTON (0832-0816-30) / 30 TABLET in 1 BOTTLE
  • ndc11
    0832-0816-30

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for deflazacort.

Graded by severity as the source publishes them — 129 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check deflazacort against other medicinesHow interaction checks work

Deflazacort · interactions on record

434 records

  • 129 severe
  • 297 moderate
  • 8 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • LonafarnibA16AX20severe
  • DesirudinB01AE01severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deflazacort in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deflazacort products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Germany · Calcort, Deflazacort Galen
  • Denmark · Deflazacort Vital Pharma Nordic
  • Spain · Defal, Deflazacort Cinfa
  • Finland · Deflazacort Vital Pharma Nordic
  • United Kingdom (Northern Ireland) · Calcort
  • Italy · Decor, Deflan
  • Netherlands · Deflazacort Xgx Pharma
  • Norway · Deflazacort Xgx Pharma
  • Portugal · Deflazacorte Acizan, Deflazacorte Almus
  • Sweden · Deflazacort

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9fddbaa7-35b5-4f24-968b-fd9f4188b706
GET /v1/drugs/9fddbaa7-35b5-4f24-968b-fd9f4188b706?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "30",
  "substance": "DEFLAZACORT",
  "productndc": "0832-0816",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA216720",
  "marketing_category": "ANDA"
}
API referenceMCP serverPlans

See everything about deflazacort.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console